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Background: The integrated treatment of first episode psychosis has been shown to improve functionality and
negative symptoms in previous studies. In this paper, we describe a study of integrated treatment (individual
psychoeducation complementary to pharmacotherapy) versus treatment as usual, comparing results at baseline
with those at 6-month re-assessment (at the end of the study) for these patients, and online training of professionals
to provide this complementary treatment, with the following objectives: 1) to compare the efficacy of individual
psychoeducation as add-on treatment versus treatment as usual in improving psychotic and mood symptoms; 2) to
compare adherence to medication, functioning, insight, social response, quality of life, and brain-derived neurotrophic
factor, between both groups; and 3) to analyse the efficacy of online training of psychotherapists.
Methods/design: This is a single-blind randomised clinical trial including patients with first episode psychosis from
hospitals across Spain, randomly assigned to either a control group with pharmacotherapy and regular sessions with
their psychiatrist (treatment as usual) or an intervention group with integrated care including treatment as usual plus
a psychoeducational intervention (14 sessions). Training for professionals involved at each participating centre was
provided by the coordinating centre (University Hospital of Álava) through video conferences. Patients are evaluated
with an extensive battery of tests assessing clinical and sociodemographic characteristics (Positive and Negative Syndrome
Scale, State-Trait Anxiety Inventory, Liebowitz Social Anxiety Scale, Hamilton Rating Scale for Depression, Scale to Assess
Unawareness of Mental Disorders, Strauss and Carpenter Prognostic Scale, Global Assessment of Functioning Scale,
Morisky Green Adherence Scale, Functioning Assessment Short Test, World Health Organization Quality of Life
instrument WHOQOL-BREF (an abbreviated version of the WHOQOL-100), and EuroQoL questionnaire), and
brain-derived neurotrophic factor levels are measured in peripheral blood at baseline and at 6 months. The statistical
analysis, including bivariate analysis, linear and logistic regression models, will be performed using SPSS.
Discussion: This is an innovative study that includes the assessment of an integrated intervention for patients with first
episode psychosis provided by professionals who are trained online, potentially making it possible to offer the
intervention to more patients.
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The definitions of the words psychotic and psychosis [1]
refer to the occurrence of delusions and hallucinations,
without specifying their nature in terms of the under-
lying disease or mental illness. The incidence of psych-
osis falls with age and is twice as high in men as in
women [2]. Around 20% of patients with a first psychotic
episode will have no further episodes [3]. This means,
however, that symptoms do recur in the great majority of
patients.
A recent meta-analysis indicated that the factors that
best predict the occurrence of relapses are failure to ad-
here to treatment, persistent substance abuse disor-
ders, negative comments from caregivers and poor
premorbid adjustment [4]. With regards to treatment,
previous studies have demonstrated that individuals
who receive early intervention including guidance on
how to improve their adherence to treatment, insight
into their illness and self-management and how to
minimise substance use have a better course and,
hence, these factors are associated with a better prog-
nosis [5-10]. Indeed, it has been observed that delays
in the treatment of psychosis tend to be associated
with slower recovery, greater suffering, a higher level
of comorbidity and greater deterioration in family and
social relationships [11]. Further, the critical period of
the disease (the first 5 years) is a relatively reliable in-
dicator of the long-term course of the disease [12,13].
Overall, it seems that interventions carried out as
early as possible improve prognosis and quality of life
in these patients.
Regarding the types of treatment for patients with first
episode psychosis, a review concluded that early psycho-
social interventions adjunctive to pharmacotherapy may
contribute to patient symptomatic and functional recov-
ery [14]. Various types of treatment have shown efficacy
in these patients. For instance, some authors recom-
mend cognitive behavioural therapy during the acute
stage of the disease or during remission [15]. However,
systematic reviews have found that integrated treatment
(including biological, psychological and social elements)
is the approach that most significantly reduces the rates
of transition to psychosis and negative symptomatology
compared to treatment as usual. Further, integrated treat-
ment has proven efficacy in various areas, being associated
with less psychotic symptomatology at 2 years follow-up,
fewer negative symptoms, better global functioning, lower
rates of substance abuse, lower doses of the second-
generation antipsychotic medications and fewer days of
hospitalization [16-19]. A clinical trial also found that this
type of treatment produces good results in the first stages
[20]. Nevertheless, there is a need for more randomised
controlled clinical trials to assess the effectiveness of these
interventions [14].On the other hand, it has been shown that disciplines,
such as cognitive behavioural therapy, that have a short-
age of formally trained clinicians could benefit from on-
line learning [21]. In particular, a European project has
demonstrated the effectiveness of teaching integrated
treatment through the web [22]. New forms of transmis-
sion of these skills could be an important way for clini-
cians to gain access to specialist knowledge, and facilitate
access to training for more clinicians.
This study hopes to shed light on these issues, with an
improved methodology; it is a pragmatic trial - that is,
there is no selection of a specific type of patients - and
the aim is to assess the effectiveness of individual
psychoeducation as well as the remote training of
therapists.
The primary objective of this study is to assess the effi-
cacy of a psychoeducation programme in improving the
symptomatology of patients; namely the positive, nega-
tive, and general symptoms of psychosis, measured using
the Positive and Negative Syndrome Scale (PANSS),
State-Trait Anxiety Inventory (STAI), and Hamilton Rat-
ing Scale for Depression (HRSD).
The secondary outcomes of interest are patient func-
tioning (measured using the Strauss and Carpenter
Prognostic Scale, Global Assessment of Functioning
(GAF) scale, Functioning Assessment Short Test (FAST)),
adherence (Morisky Green Medication Adherence Scale),
insight (Scale to Assess Unawareness of Mental Disorders
(SUMD)), social response (Liebowitz Social Anxiety Scale
(LSAS)), quality of life (World Health Organization Quality
of Life instrument WHOQOL-BREF (an abbreviated ver-
sion of the WHOQOL-100) and the EuroQoL question-
naire), and brain-derived neurotrophic factor (BDNF) level.
We also want to analyse the efficacy of online training
of psychotherapists.
In this paper, we describe in detail the study design,
patient selection and evaluation, the programme of psy-
choeducation under study, and training of professionals.
It is an intervention study of integrated treatment for
patients with first episode psychosis, with the innovation
that the participating therapists will receive remote
training.
Methods
Design
We registered this single-blind randomised clinical trial
in 2013 (identifier NCT01783457). Patients with a first
episode of psychosis between 2010 and 2014 are to be
included and randomly assigned to one of two treatment
groups: the control group, receiving pharmacotherapy
together with regular sessions with a psychiatrist (treat-
ment as usual), and the intervention group receiving in-
tegrated treatment, namely treatment as usual plus a
psychoeducational intervention (12 main sessions and 2
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as the first time a patient displayed positive psychotic
symptoms of delusions and/or hallucinations.
We are recruiting patients from five psychiatric cen-
tres (University Hospital of Álava, Clinic Hospital of
Barcelona, Clinical Foundation of Valencia, University
Hospital of Bellvitge, and University of Valencia) that
agreed to take part in the e-learning project. In all
centres, the clinicians recruit subjects who show
psychotic symptoms for the first time, and who meet
the inclusion criteria (listed below). To obtain 90%
power to detect differences in the means at the 5%
level of significance, we have estimated that we need
to enrol 130 patients in each group (study group and
controls) (alpha = 0.05; beta = 0.10; n = 260).
The treatment is being supervised by one clinician
(PV) trained by a highly experienced clinician at the
University Hospital of Álava (SB), while the evaluations
in all centres are conducted by other clinicians blind to
patient allocation.
Inclusion criteria
For patients to be included, they must have experienced
a first episode of psychosis. All those included must have
met Diagnostic and Statistical Manual of Mental Disorders
4th edition text revised (DSM-IV-TR) criteria for one of the
following within the previous 5 years: schizophreniform
disorder, schizoaffective disorder, brief psychotic disorder,
delusional disorder, non-specified psychotic disorder, bipo-
lar disorder with psychotic symptoms, or major depressive
disorder with psychotic symptoms. In addition to giving in-
formed consent, they must also be between 18 and 45
years old and speak good Spanish.
Exclusion criteria
Subjects with mental retardation, organic brain disorders
or the presence of any comorbid condition that could
hinder communication, or drug abuse as a primary diag-
nosis, were excluded.
Ethical considerations
The study is conducted in compliance with local regula-
tions and internationally established principles of the
Declaration of Helsinki (64th World Medical Association
General Assemble, Fortaleza, Brazil, 2013). The study
and protocol were approved by the Clinical Research
Ethics Committee of each participating health centre
(University Hospital of Álava: HS/PI2010009: Clinic
Hospital of Barcelona: 2010/5890, Clinical Foundation
of Valencia; 2010/2904, University Hospital of Bellvitge:
PR079/10, and University of Valencia: 2010/2904). Before
inclusion, all patients are required to sign an informed
consent form that includes a specific section covering gen-
etic testing (for the BDNF analysis, see below).Randomisation
All individuals with first episode psychosis that meet the
selection criteria are randomised with random allocation
software. For this purpose, all the groups from the par-
ticipating centres send the initials of each patient re-
cruited to researchers at the coordinating centre who
specify the allocation of the patient (to the control or
intervention group); the person in charge of the assess-
ments is blind to this process.
Pharmacotherapy
For all participants, the pharmacological treatment used
is that which patients have been prescribed by their
psychiatrists, independent of their participation in the
study.
Patient assessment
Data are collected on the wide range of clinical and
demographic variables detailed below and are entered
on a data collection form. All the patients are assessed
at baseline and have been or will be assessed at 6
months after inclusion in the study, which corresponds
to the end of the psychoeducational programme in the
case of the intervention group.
Demographic data
Data are collected on age, sex, level of education, living
arrangements and employment status.
Symptomatology
Participants’ symptoms are assessed using the PANSS
[23]. This instrument is composed of 30 items that
assess positive and negative symptoms as well as the
general psychopathology of the disorder. Each item is
measured using a 7-point Likert scale reflecting the se-
verity of symptoms, from 1 (none at all) to 7 (extreme
symptoms). This scale has been validated in Castilian
Spanish [24].
Trait and state anxiety are measured using the STAI
[25]. This instrument has two parts: one assesses the
anxiety experienced by patients in the previous week
(state) using 20 items with four response options; while
other part, also composed of 20 items with four response
options, assesses their usual reactions to certain situa-
tions (trait anxiety). The STAI was adapted from the ver-
sion described in a Spanish paper by Bermúdez in 1978
[26]; across all these items the mean and the reliability
(Cronbach’s alpha and test-retest correlation) are similar
to those of the original version [27].
Patients’ social anxiety is assessed using the LSAS [28],
and its psychometric properties have been found to be
satisfactory in the Spanish population [29]. Lastly, mood
is evaluated using the HRSD [30], which has also been
validated in Castilian Spanish [31].
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mation on the number of relapses and hospital admis-
sions (psychotic episodes) and the dates on which they
occur for 2 years follow-up, the psychopharmacotherapy
administered, family history of mental health problems,
and record of substance use both before and after the
intervention.
Patient awareness of their disease
Patient insight into their illness is measured using
SUMD [32]. This scale provides broad assessment of pa-
tient thoughts and beliefs regarding their disease and
medication. The Spanish adaptation of the SUMD is
equivalent to the original version, and it has a similar re-
liability and external validity [33].
Prognosis
Prognosis is explored using the Strauss and Carpenter
Prognostic Scale [34-36], an instrument that assesses the
best status of the patient in the previous year in four
areas: hospitalisations, work, social activity, and global
functioning and, on the other hand, symptoms consid-
ering the previous month only. It is an interview-
administered instrument with Likert-type response
options ranging from 0 to 4, higher scores indicating a
better prognosis. It has been validated in Castilian
Spanish for schizophrenia [37].
Functioning
The overall function of patients is rated using a Spanish
version of the GAF scale. This scale is recommended for
Axis V in the multiaxial system of DSM-IV-TR [38] and
is based on the opinion of clinicians regarding the level
of general activity and functioning of patients. It has
been validated in individuals with severe mental disor-
ders [39].
Functional status is also assessed using FAST [40].
This is an interview-administered scale that assesses a
patient’s functioning over the previous 2 weeks in six
areas: autonomy, occupational functioning, cognitive
functioning, financial issues, interpersonal relationships
and leisure time. The FAST showed strong psychomet-
ric properties in Spanish individuals with first episode
psychosis [41].
Treatment adherence
Adherence is estimated using the Morisky Medication
Adherence Scale [42]. This instrument has been vali-
dated for the Spanish population [43]. It has four
questions and assesses the attitudes of the patients to-
wards their treatment. Patients with a score of 4 were
considered to have ‘good’ adherence, while those with
a score between 0 and 3 were classified as having ‘bad’
adherence.Quality of life
The quality of life is measured using two instruments.
First, the World Health Organization Quality of Life
WHOQOL-BREF questionnaire [44] was used; this short
version being composed of 26 items exploring four di-
mensions: physical health, psychological health, social
relationships and the environment. Spanish field trials
have confirmed that this questionnaire has adequate psy-
chometric properties [45].
Second, the EuroQoL questionnaire [46] was used.
The main part of this measures five dimensions (EQ-
5D): mobility, self-care, usual activities, pain/discomfort
and anxiety/depression. It also contains a visual analogue
scale (EQ-VAS) represented by a vertical line on which
subjects rate their self-perceived health status from 0
(the worst) to 100 (the best imaginable health status).
The questionnaire is considered a simple, valid and
practical measure and the Spanish version has been
validated [47].
All the instruments used have demonstrated ad-
equate psychometric properties and have been used in
many other studies. Interviews are conducted by clini-
cians who have good inter-rater reliability for the
scales used (PANSS, kappa = 0.80; STAI, kappa = 0.77;
GAF, kappa = 0.95; LSAS, kappa = 0.83; HDRS-21, kappa
0.79; SUMD, Kappa = 0.81; Strauss–Carpenter, kappa = 0.
79; Morisky Medication Adherence Scale, Kappa = 0.94,
FAST, Kappa = 0.88, WHOQOL-BREF, Kappa = 0.81
and Euroquol, Kappa = 0.78).Biochemical analysis
To investigate BDNF in peripheral blood, blood samples
are collected in the morning (on two occasions, like the
other assessments, once at baseline and once at 6
months after inclusion). Plasma BDNF levels are mea-
sured using a BDNF Sandwich enzyme-linked immuno-
sorbent assay kit (CYT306; EMD Millipore Corporation,
Billerica, MA, USA), according to the manufacturer’s in-
structions. Blood cells are immediately separated from
the plasma and processed. Standard curves are con-
structed using plasma duplicates. The absorption at 450
nm is measured with a Synergy HT microplate reader
(BioTek Instruments, Winooski, VT, USA).Online training
The coordinating group carried out the training of the
therapists in the participating centres, via teleconferen-
cing (WebEx Training Center). The course consisted of
12 modules and 2 booster sessions, corresponding to the
14 sessions of the psychoeducational programme, and all
the participating groups received the same theoretical
content. Once all the materials had been provided and
explained, participating groups were asked to perform a
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this before starting the following module.
In addition, all the therapists participating in the on-
line training had to prepare a case study with theoretical
and practical elements and correctly complete a task
under the supervision of a psychotherapist with exten-
sive experience in the field of psychoeducation, before
they themselves carried out the psychoeducational inter-
vention with the patients. As well as providing written
support material, we attempted to ensure the correct in-
tegration of knowledge presented by giving feedback,
correcting answers participants gave during sessions,
and correcting hypothetical cases presented. At the end
of each module, all the therapists were required to
complete a form recording the learning objectives
covered in the module and testing their knowledge of
theoretical and practical aspects of the psychoeducation
programme.Intervention programme
Integrated treatment
The psychoeducational programme has 14 1-hour ses-
sions (12 main sessions and 2 booster sessions), fort-
nightly, for a period of 6 months, focused on improving
patient insight into their illness, treatment adherence,
prodromal identification, early intervention to prevent
relapses, healthy lifestyles, techniques for managing anx-
iety, social skills and problem solving.
The programme includes the following sessions:
1. What is a first episode of psychosis?
2. The challenge and importance of insight into
vulnerability
3. Symptom recognition
4. Prevention of relapses: protective and risk factors
5. What can I do if I note the symptoms emerging
again?
6. Treatment adherence
7. Healthy lifestyles: sleep and sexuality
8. Healthy lifestyles: substance use
9. Anxiety management techniques (I)
10. Anxiety management techniques (II)
11. Social skills: assertiveness techniques
12. Problem-solving techniques
We have checked the completeness of the training
with respect to the administration of the sessions both
in terms of content and their structure. The psychoedu-
cational sessions are run with the same interval between
sessions in all the centres. Further, the therapists give
the psychoeducational intervention to all patients in the
same way and provide the same information, enhancing
the reliability of the study.If patients report any personal, social, work-related or
family problems during the sessions, they are to be
helped using cognitive behavioural techniques (psycho-
therapeutic intervention). Lastly, if patients have any
question regarding what they are taught during the ses-
sions, or about their condition, they can call a telephone
helpline in working hours (between 08.00 and 15.00
from Monday to Friday). The aim of this service is to fa-
cilitate patient access to information and address any
questions they might have.
Treatment as usual
Treatment as usual refers to the treatment that is rou-
tinely provided to patients with first episode psychosis
on the Spanish National Health Service. It consists of
ambulatory psychopharmacotherapy with regular ses-
sions with an assigned psychiatrist, corresponding to a
personalised psychiatric approach to their management.
Data processing
We used Gridsam, the central database of the Spanish
research network for mental health (CIBERSAM). This
database facilitates the merging of large amounts of data
and access to the records.
Comparisons of baseline characteristics of the sample
will be made with χ2-tests for categorical variables and
the Student’s t-test or Mann Whitney U test for quanti-
tative variables. Within-group changes in symptomatol-
ogy and functioning during treatment will be examined
using paired t-tests.
Univariate analyses of covariance will be conducted to
investigate differences between groups. For this, the in-
dependent variable is the group assignment (integrated
treatment versus control) and the dependent variable is
the respective clinical or functional outcome score post-
treatment. Recurrence-free curve analysis will be per-
formed using Kaplan–Meyer survival analysis to analyse
the relapses in the groups during the follow-up. This
analysis will be performed on an intention-to-treat basis,
with patients being analysed in the treatment group to
which they were randomised.
In addition, a logistic regression model will be used
to analyse the association between clinical variables.
Finally, we will also build a logistic regression model
to explore factors associated with changes in variables
during follow-up.
The outcomes will be reported with 95% confidence
intervals. All data will be analysed using SPSS (version
21.0; IBM Corp. Released 2012. IBM SPSS Statistics for
Windows, Version 21.0. Armonk, NY: IBM Corp.
Discussion
The project we describe in this paper represents an
innovation in our setting given that it uses an online
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question and answer sessions are carried out remotely,
facilitating access by all professionals, and reducing fi-
nancial and time costs.
On the other hand, the integrated treatment itself is
based on strategies that have proven to be effective, and,
depending on the results, this project might lead to its
adoption in routine practice in our setting. In addition,
the close monitoring of first episodes of psychosis asso-
ciated with the study provides extra data, improving our
knowledge and understanding of the situation of these
patients and, in turn, allowing treatments to be opti-
mised. Finally, the proposed intervention at the onset of
the disease will enable the patients to reap the benefits
of early intervention, not only at the pharmacological
level, but also in the areas addressed by adjunctive treat-
ments that have proven to be effective [48], but that are
not currently in the portfolio of services offered in our
health centres.
With regards to the limitations of this study, first of all
some variables are measured by self-report and patients
could under- or overestimated their symptoms, but pa-
tients are also assessed by clinicians. Further, although
the scales employed are among the most widely used by
clinicians and researchers in this type of patient, results
may not be comparable between studies if different in-
struments are used. Finally, although we have already re-
cruited many patients and recruitment continues to the
end of 2014, the power of the study would be increased
with a larger sample size and, to assess the longer-term
impact of the intervention, a longer monitoring period
should be considered (>6 months). On the other hand,
this is the first study in our setting assessing this type of
therapy and this type of innovative training with a rigor-
ous methodology (structure and content).
Trial status
We have not completed patient recruitment at the time
of submission.
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